{"SLR NAME":"Effectiveness and Safety of Chloroquine or Hydroxychloroquine as a mono-therapy or in combination with Azithromycin in the treatment of COVID-19 patients: Systematic Review and Meta-Analysis","References":[{"title1":"Pattern of SARS-CoV-2 infection among dependant elderly residents living in long-term care facilities in Marseille, France, March–June 2020","References":[{"title2":"High impact of COVID-19 in long-term care facilities, suggestion for monitoring in the EU/EEA, May 2020","References":[{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"},{"title3":"High%20impact%20of%20COVID-19%20in%20long-term%20care%20facilities,%20suggestion%20for%20monitoring%20in%20the%20EU/EEA,%20May%202020"}]},{"title2":"Potential lethal outbreak of coronavirus disease (COVID-19) among the elderly in retirement homes and long-term facilities, France, March 2020","References":[{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"},{"title3":"Potential%20lethal%20outbreak%20of%20coronavirus%20disease%20(COVID-19)%20among%20the%20elderly%20in%20retirement%20homes%20and%20long-term%20facilities,%20France,%20March%202020"}]},{"title2":"COVID-19 in long-term care facilities for the elderly: laboratory screening and disease dissemination prevention strategies","References":[]},{"title2":"Risk Factors Associated With Mortality Among Residents With Coronavirus Disease 2019 (COVID-19) in Long-term Care Facilities in Ontario, Canada","References":[{"title3":"Risk%20Factors%20Associated%20With%20Mortality%20Among%20Residents%20With%20Coronavirus%20Disease%202019%20(COVID-19)%20in%20Long-term%20Care%20Facilities%20in%20Ontario,%20Canada"},{"title3":"Risk%20Factors%20Associated%20With%20Mortality%20Among%20Residents%20With%20Coronavirus%20Disease%202019%20(COVID-19)%20in%20Long-term%20Care%20Facilities%20in%20Ontario,%20Canada"},{"title3":"Risk%20Factors%20Associated%20With%20Mortality%20Among%20Residents%20With%20Coronavirus%20Disease%202019%20(COVID-19)%20in%20Long-term%20Care%20Facilities%20in%20Ontario,%20Canada"},{"title3":"Risk%20Factors%20Associated%20With%20Mortality%20Among%20Residents%20With%20Coronavirus%20Disease%202019%20(COVID-19)%20in%20Long-term%20Care%20Facilities%20in%20Ontario,%20Canada"},{"title3":"Risk%20Factors%20Associated%20With%20Mortality%20Among%20Residents%20With%20Coronavirus%20Disease%202019%20(COVID-19)%20in%20Long-term%20Care%20Facilities%20in%20Ontario,%20Canada"}]},{"title2":"Hydroxychloroquine and chloroquine: a potential and controversial treatment for COVID-19","References":[{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"},{"title3":"Hydroxychloroquine%20and%20chloroquine:%20a%20potential%20and%20controversial%20treatment%20for%20COVID-19"}]},{"title2":"Outcomes of 3,737 COVID-19 patients treated with hydroxychloroquine/azithromycin and other regimens in Marseille, France: A retrospective analysis","References":[{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"},{"title3":"Outcomes%20of%203,737%20COVID-19%20patients%20treated%20with%20hydroxychloroquine/azithromycin%20and%20other%20regimens%20in%20Marseille,%20France:%20A%20retrospective%20analysis"}]},{"title2":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial","References":[{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open%20label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open%20label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open%20label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open%20label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open%20label%20non-randomized%20clinical%20trial"}]},{"title2":"Clinical and microbiological effect of a combination of hydroxychloroquine and azithromycin in 80 COVID-19 patients with at least a six-day follow up: an observational study","References":[{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"},{"title3":"Clinical%20and%20microbiological%20effect%20of%20a%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%2080%20COVID-19%20patients%20with%20at%20least%20a%20six-day%20follow%20up:%20an%20observational%20study"}]},{"title2":"Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France","References":[{"title3":"Early%20treatment%20of%20COVID-19%20patients%20with%20hydroxychloroquine%20and%20azithromycin:%20A%20retrospective%20analysis%20of%201061%20cases%20in%20Marseille,%20France"},{"title3":"Early%20treatment%20of%20COVID-19%20patients%20with%20hydroxychloroquine%20and%20azithromycin:%20A%20retrospective%20analysis%20of%201061%20cases%20in%20Marseille,%20France"},{"title3":"Early%20treatment%20of%20COVID-19%20patients%20with%20hydroxychloroquine%20and%20azithromycin:%20A%20retrospective%20analysis%20of%201061%20cases%20in%20Marseille,%20France"},{"title3":"Early%20treatment%20of%20COVID-19%20patients%20with%20hydroxychloroquine%20and%20azithromycin:%20A%20retrospective%20analysis%20of%201061%20cases%20in%20Marseille,%20France"},{"title3":"Early%20treatment%20of%20COVID-19%20patients%20with%20hydroxychloroquine%20and%20azithromycin:%20A%20retrospective%20analysis%20of%201061%20cases%20in%20Marseille,%20France"}]},{"title2":"Rapid viral diagnosis and ambulatory management of suspected COVID-19 cases presenting at the infectious diseases referral hospital in Marseille, France, - January 31st to March 1st, 2020: A respiratory virus snapshot","References":[{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"},{"title3":"Rapid%20viral%20diagnosis%20and%20ambulatory%20management%20of%20suspected%20COVID-19%20cases%20presenting%20at%20the%20infectious%20diseases%20referral%20hospital%20in%20Marseille,%20France,%20-%20January%2031st%20to%20March%201st,%202020:%20A%20respiratory%20virus%20snapshot"}]},{"title2":"Coronavirus Disease 2019 Outcomes in French Nursing Homes That Implemented Staff Confinement With Residents","References":[{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"},{"title3":"Coronavirus%20Disease%202019%20Outcomes%20in%20French%20Nursing%20Homes%20That%20Implemented%20Staff%20Confinement%20With%20Residents"}]},{"title2":"Louie JK, Scott HM, DuBois A, Sturtz N, Lu W, Stoltey J, et al. Lessons from mass-testing for COVID-19 in long-term care facilities for the elderly in San Francisco. Clin Infect Dis 2020:ciaa1020.","References":[]},{"title2":"Atypical clinical presentation of COVID-19 infection in residents of a long-term care facility","References":[{"title3":"Atypical%20clinical%20presentation%20of%20COVID-19%20infection%20in%20residents%20of%20a%20long-term%20care%20facility"},{"title3":"Atypical%20clinical%20presentation%20of%20COVID-19%20infection%20in%20residents%20of%20a%20long-term%20care%20facility"},{"title3":"Atypical%20clinical%20presentation%20of%20COVID-19%20infection%20in%20residents%20of%20a%20long-term%20care%20facility"},{"title3":"Atypical%20clinical%20presentation%20of%20COVID-19%20infection%20in%20residents%20of%20a%20long-term%20care%20facility"},{"title3":"Atypical%20clinical%20presentation%20of%20COVID-19%20infection%20in%20residents%20of%20a%20long-term%20care%20facility"},{"title3":"Atypical%20clinical%20presentation%20of%20COVID-19%20infection%20in%20residents%20of%20a%20long-term%20care%20facility"},{"title3":"Atypical%20clinical%20presentation%20of%20COVID-19%20infection%20in%20residents%20of%20a%20long-term%20care%20facility"}]},{"title2":"Asymptomatic SARS-CoV-2 infection in Belgian long-term care facilities","References":[{"title3":"Asymptomatic%20SARS-CoV-2%20infection%20in%20Belgian%20long-term%20care%20facilities"},{"title3":"Asymptomatic%20SARS-CoV-2%20infection%20in%20Belgian%20long-term%20care%20facilities"},{"title3":"Asymptomatic%20SARS-CoV-2%20infection%20in%20Belgian%20long-term%20care%20facilities"},{"title3":"Asymptomatic%20SARS-CoV-2%20infection%20in%20Belgian%20long-term%20care%20facilities"},{"title3":"Asymptomatic%20SARS-CoV-2%20infection%20in%20Belgian%20long-term%20care%20facilities"}]},{"title2":"COVID-19 mortality risk factors in older people in a long-term care center","References":[{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"},{"title3":"COVID-19%20mortality%20risk%20factors%20in%20older%20people%20in%20a%20long-term%20care%20center"}]},{"title2":"The association of treatment with hydroxychloroquine and hospital mortality in COVID-19 patients","References":[{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"},{"title3":"The%20association%20of%20treatment%20with%20hydroxychloroquine%20and%20hospital%20mortality%20in%20COVID-19%20patients"}]},{"title2":"Treatment with hydroxychloroquine, azithromycin, and combination in patients hospitalized with COVID-19","References":[{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"},{"title3":"Treatment%20with%20hydroxychloroquine,%20azithromycin,%20and%20combination%20in%20patients%20hospitalized%20with%20COVID-19"}]},{"title2":"Low-dose hydroxychloroquine therapy and mortality in hospitalised patients with COVID-19: a nationwide observational study of 8075 participants","References":[{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"},{"title3":"Low-dose%20hydroxychloroquine%20therapy%20and%20mortality%20in%20hospitalised%20patients%20with%20COVID-19:%20a%20nationwide%20observational%20study%20of%208075%20participants"}]},{"title2":"(CORIST) Collaboration. Use of hydroxychloroquine in hospitalised COVID-19 patients is associated with reduced mortality: Findings from the observational multicentre Italian CORIST study","References":[]},{"title2":"Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study","References":[{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"},{"title3":"Long-term%20hydroxychloroquine%20use%20in%20patients%20with%20rheumatic%20conditions%20and%20development%20of%20SARS-CoV-2%20infection:%20a%20retrospective%20cohort%20study"}]},{"title2":"The unfinished story of hydroxychloroquine in COVID-19: the right anti-inflammatory dose at the right moment","References":[{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"},{"title3":"The%20unfinished%20story%20of%20hydroxychloroquine%20in%20COVID-19:%20the%20right%20anti-inflammatory%20dose%20at%20the%20right%20moment"}]},{"title2":"The effect of frailty on survival in patients with COVID-19 (COPE): a multicentre, European, observational cohort study","References":[{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"},{"title3":"The%20effect%20of%20frailty%20on%20survival%20in%20patients%20with%20COVID-19%20(COPE):%20a%20multicentre,%20European,%20observational%20cohort%20study"}]},{"title2":"Impact of medical care, including use of anti-infective agents, on prognosis of COVID-19 hospitalized patients over time","References":[{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"},{"title3":"Impact%20of%20medical%20care,%20including%20use%20of%20anti-infective%20agents,%20on%20prognosis%20of%20COVID-19%20hospitalized%20patients%20over%20time"}]}]},{"title1":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","References":[{"title2":"Race to find COVID-19 treatments accelerates","References":[]},{"title2":"In vitro antiviral activity and projection of optimized dosing design of hydroxychloroquine for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)","References":[]},{"title2":"A rush to judgment? Rapid reporting and dissemination of results and its consequences regarding the use of hydroxychloroquine for covid-19","References":[]},{"title2":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","References":[{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"}]},{"title2":"No evidence of rapid antiviral clearance or clinical benefit with the combination of hydroxychloroquine and azithromycin in patients with severe covid-19 infection","References":[{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"},{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"},{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"},{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"},{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"},{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"},{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"},{"title3":"No%20evidence%20of%20rapid%20antiviral%20clearance%20or%20clinical%20benefit%20with%20the%20combination%20of%20hydroxychloroquine%20and%20azithromycin%20in%20patients%20with%20severe%20covid-19%20infection"}]},{"title2":"Efficacy of hydroxychloroquine in patients with COVID-19: results of a randomized clinical trial","References":[]},{"title2":"Covid-19: US gives emergency approval to hydroxychloroquine despite lack of evidence","References":[]},{"title2":"Use of hydroxychloroquine and chloroquine during the covid-19 pandemic: what every clinician should know","References":[]},{"title2":"Using big data to emulate a target trial when a randomized trial is not available","References":[]},{"title2":"Acute respiratory distress syndrome: the Berlin Definition","References":[]},{"title2":"Stratification and weighting via the propensity score in estimation of causal treatment effects: a comparative study [correction in: Stat Med 2017;36:2320]","References":[]},{"title2":"Marginal structural models and causal inference in epidemiology","References":[]},{"title2":"Covid-19 and angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: what is the evidence?","References":[{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"},{"title3":"Covid-19%20and%20angiotensin-converting%20enzyme%20inhibitors%20and%20angiotensin%20receptor%20blockers:%20what%20is%20the%20evidence?"}]},{"title2":"Moving towards best practice when using inverse probability of treatment weighting (IPTW) using the propensity score to estimate causal treatment effects in observational studies","References":[{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"},{"title3":"Moving%20towards%20best%20practice%20when%20using%20inverse%20probability%20of%20treatment%20weighting%20(IPTW)%20using%20the%20propensity%20score%20to%20estimate%20causal%20treatment%20effects%20in%20observational%20studies"}]},{"title2":"The third international consensus definitions for sepsis and septic shock (Sepsis-3)","References":[{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"},{"title3":"The%20third%20international%20consensus%20definitions%20for%20sepsis%20and%20septic%20shock%20(Sepsis-3)"}]},{"title2":"Prognostic accuracy of sepsis-3 criteria for in-hospital mortality among patients with suspected infection presenting to the emergency department","References":[]},{"title2":"Invited commentary: composite outcomes as an attempt to escape from selection bias and related paradoxes","References":[]},{"title2":"Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China","References":[]},{"title2":"Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China","References":[{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"},{"title3":"Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan,%20China"}]},{"title2":"A trial of lopinavir-ritonavir in adults hospitalized with severe covid-19","References":[{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"},{"title3":"A%20trial%20of%20lopinavir-ritonavir%20in%20adults%20hospitalized%20with%20severe%20covid-19"}]},{"title2":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","References":[{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"}]},{"title2":"Clinical and virological data of the first cases of COVID-19 in Europe: a case series","References":[{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"},{"title3":"Clinical%20and%20virological%20data%20of%20the%20first%20cases%20of%20COVID-19%20in%20Europe:%20a%20case%20series"}]},{"title2":"Hydroxychloroquine: a multifaceted treatment in lupus","References":[]},{"title2":"Mechanism of endosomal TLR inhibition by antimalarial drugs and imidazoquinolines","References":[]}]},{"title1":"Outcomes of Hydroxychloroquine Usage in United States Veterans Hospitalized with COVID-19","References":[{"title2":"Hydroxychloroquine, a less toxic derivative of chloroquine, is effective in inhibiting SARS-CoV-2 infection in vitro","References":[{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"},{"title3":"Hydroxychloroquine,%20a%20less%20toxic%20derivative%20of%20chloroquine,%20is%20effective%20in%20inhibiting%20SARS-CoV-2%20infection%20in%20vitro"}]},{"title2":"Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial","References":[{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"},{"title3":"Hydroxychloroquine%20and%20azithromycin%20as%20a%20treatment%20of%20COVID-19:%20results%20of%20an%20open-label%20non-randomized%20clinical%20trial"}]},{"title2":"The QT interval in patients with COVID-19 treated with hydroxychloroquine and azithromycin","References":[]},{"title2":"A pilot study of hydroxychloroquine in treatment of patients with moderate COVID-19","References":[]},{"title2":"Clinical efficacy of hydroxychloroquine in patients with covid-19 pneumonia who require oxygen: observational comparative study using routine care data","References":[]},{"title2":"Assessment of QT intervals in a case series of patients with coronavirus disease 2019 (COVID-19) infection treated with hydroxychloroquine alone or in combination with azithromycin in an intensive care unit","References":[]},{"title2":"Risk of QT interval prolongation associated with use of hydroxychloroquine with or without concomitant azithromycin among hospitalized patients testing positive for coronavirus disease 2019 (COVID-19)","References":[]},{"title2":"Against pandemic research exceptionalism","References":[]},{"title2":"Outcomes of hydroxychloroquine usage in United States veterans hospitalized with Covid-19","References":[{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"},{"title3":"Outcomes%20of%20hydroxychloroquine%20usage%20in%20United%20States%20veterans%20hospitalized%20with%20Covid-19"}]},{"title2":"Observational study of hydroxychloroquine in hospitalized patients with Covid-19","References":[{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"},{"title3":"Observational%20study%20of%20hydroxychloroquine%20in%20hospitalized%20patients%20with%20Covid-19"}]},{"title2":"Association of treatment with hydroxychloroquine or azithromycin with in-hospital mortality in patients with COVID-19 in New York state","References":[{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"},{"title3":"Association%20of%20treatment%20with%20hydroxychloroquine%20or%20azithromycin%20with%20in-hospital%20mortality%20in%20patients%20with%20COVID-19%20in%20New%20York%20state"}]},{"title2":"Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis","References":[]},{"title2":"Hydroxychloroquine in patients with mainly mild to moderate coronavirus disease 2019: open label, randomised controlled trial","References":[{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"},{"title3":"Hydroxychloroquine%20in%20patients%20with%20mainly%20mild%20to%20moderate%20coronavirus%20disease%202019:%20open%20label,%20randomised%20controlled%20trial"}]},{"title2":"Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study","References":[{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"},{"title3":"Clinical%20course%20and%20risk%20factors%20for%20mortality%20of%20adult%20inpatients%20with%20COVID-19%20in%20Wuhan,%20China:%20a%20retrospective%20cohort%20study"}]},{"title2":"Baseline characteristics and outcomes of 1591 patients infected with SARS-CoV-2 admitted to ICUs of the Lombardy Region, Italy","References":[]},{"title2":"Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area","References":[]},{"title2":"Dosage of antimalarial drugs for children with juvenile rheumatoid arthritis and systemic lupus erythematosus. A clinical study with determination of serum concentrations of chloroquine and hydroxychloroquine","References":[]},{"title2":"Bioavailability of hydroxychloroquine tablets in healthy volunteers","References":[]},{"title2":"Effect of high vs low doses of chloroquine diphosphate as adjunctive therapy for patients hospitalized with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection: a randomized clinical trial","References":[]},{"title2":"Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019 : COVID-NET, 14 states, March 1-30, 2020","References":[{"title3":"Hospitalization%20rates%20and%20characteristics%20of%20patients%20hospitalized%20with%20laboratory-confirmed%20coronavirus%20disease%202019%20:%20COVID-NET,%2014%20states,%20March%201-30,%202020"},{"title3":"Hospitalization%20rates%20and%20characteristics%20of%20patients%20hospitalized%20with%20laboratory-confirmed%20coronavirus%20disease%202019%20:%20COVID-NET,%2014%20states,%20March%201-30,%202020"},{"title3":"Hospitalization%20rates%20and%20characteristics%20of%20patients%20hospitalized%20with%20laboratory-confirmed%20coronavirus%20disease%202019%20:%20COVID-NET,%2014%20states,%20March%201-30,%202020"},{"title3":"Hospitalization%20rates%20and%20characteristics%20of%20patients%20hospitalized%20with%20laboratory-confirmed%20coronavirus%20disease%202019%20:%20COVID-NET,%2014%20states,%20March%201-30,%202020"}]},{"title2":"Disparities in outcomes among COVID-19 patients in a large health care system in California","References":[]},{"title2":"Clinical characteristics of coronavirus disease 2019 in China","References":[{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"},{"title3":"Clinical%20characteristics%20of%20coronavirus%20disease%202019%20in%20China"}]},{"title2":"Statistical methods for analyzing right-censored length-biased data under cox model","References":[{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"},{"title3":"Statistical%20methods%20for%20analyzing%20right-censored%20length-biased%20data%20under%20cox%20model"}]},{"title2":"Performance of time-dependent propensity scores: a pharmacoepidemiology case study","References":[{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"},{"title3":"Performance%20of%20time-dependent%20propensity%20scores:%20a%20pharmacoepidemiology%20case%20study"}]},{"title2":"Performance evaluation of regression splines for propensity score adjustment in post-market safety analysis with multiple treatments","References":[]},{"title2":"Bias associated with using the estimated propensity score as a regression covariate","References":[{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"},{"title3":"Bias%20associated%20with%20using%20the%20estimated%20propensity%20score%20as%20a%20regression%20covariate"}]},{"title2":"Propensity score matching and subclassification in observational studies with multi-level treatments","References":[]},{"title2":"On principles for modeling propensity scores in medical research","References":[]}]}]}